;
Day of late-breaking abstracts in H&N cancer
💊Trying to leverage LAG-3 to enhance the activity of APCs against HNSCC
📯New opportunity for TDxd in SGC to show their activity
📊Unlocking old questions about anti-androgen therapy vs CT in SGC
@ttccgroup @IReC_RM @SGCancerUK
Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication.
https://www.nature.com/articles/s41571-024-00924-9
Outcomes of Immune Checkpoint Inhibitors for Recurrent or Metastatic HNSCC
Outcomes of Immune Checkpoint Inhibitors for Recurrent or Metastatic HNSCC
This cohort study investigates survival in US patients receiving immune checkpoint inhibitor–based treatment for recurre...
jamanetwork.com
Some Considerations on the Treatment and Prognosis of the Most Common Malignant Tumors of the Larynx @ORL_HUCA @HUCA_Asturias @uniovi_info @FINBAsturias
TTCC en cifras
Entidades Colaboradoras
WEB en renovación gracias a la colaboración de Bayer
